Phase 2Recruiting
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Phase 2 Study of Venetoclax-containing Therapy in Combination With HLA-mismatched Mobilized Peripheral Blood Mononuclear Cell Infusion for Newly Diagnosed Acute Myeloid Leukemia
- Sponsor
- Beijing 302 Hospital (Academic or other)
- Enrolment
- 50 planned
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Venetoclax; Azacitidine (AZA); Daunorubicin; Idarubicin（IDA）; Cytarabine (Ara-C); GPBMC infusion
- Ages
- adults, older adults
- Registry
- NCT07078591
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult patients with newly diagnosed acute myeloid leukemia (AML).
Primary outcomes
- Overall survival (OS)
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started